Table 1.
Baseline demographics and clinical characteristics of patients infected by SARS-CoV-2 per year of inclusion and differences over the years.
| Characteristics | Year | Total | P-value | ||
|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | Δ 2020–2021 versus 2022# | ||
| N = 39 | N = 35 | N = 106 | N = 180 | ||
| Age, median age in years (min-max) at COVID-19 | 58.5 (5.2–72.8) | 55.2 (17.6–72.6) | 61.3 (20.2–78.4) | 58.9 (5.2–78.4) | |
| 56.2 (5.2–72.8) | 61.3 (20.2–78.4) | 0.01** | |||
| Female sex, N (%) | 17 (43.6) | 17 (48.6) | 34 (32.1) | 68 (37.8) | 0.06 |
| CAR T-cell therapy indication, N (%) | 0.7 | ||||
| Acute leukemia | 5 (12.8) | 5 (14.3) | 10 (9.4) | 20 (11.1) | |
| B-NHL | 32 (82.1) | 27 (77.1) | 89 (84.0) | 148 (82.2) | |
| Multiple myeloma | 2 (5.1) | 3 (8.6) | 7 (6.6) | 12 (6.7) | |
| Disease status at time of COVID-19 diagnosis, N (%) | 0.09 | ||||
| Relapse/Progression | 8 (20.5) | 7 (20) | 13 (12.3) | 28 (15.5) | |
| Partial response | 4 (10.3) | 5 (14.3) | 9 (8.5) | 18 (10) | |
| Complete response | 27 (69.2) | 22 (62.9) | 81 (76.4) | 130 (72.2) | |
| Unknown | 0 (0.0) | 1 (2.9) | 3 (2.8) | 4 (2.2) | |
| Metabolic comorbidity*, N (%) | 11 (28.2) | 10 (28.6) | 36 (34.0) | 57 (31.7) | 0.3 |
| Unknown | 0 (0.0) | 5 (14.3) | 10 (9.4) | 15 (8.3) | |
| Lansky/Karnofsky-score < 70 at COVID-19 diagnosis, N (%) | 9 (23.1) | 3 (8.6) | 8 (7.5) | 20 (11.1) | 0.1 |
| Unknown | 0 (0.0) | 1 (2.9) | 15 (14.2) | 16 (8.9) | |
| Median time from CAR-T to COVID-19 diagnosis, months (min days-max months) | 7.7 (1–17.5) | 7.4 (6–37.1) | 6.4 (5–42.5) | 7.2 (1–42.5) | 0.6 |
| Symptoms at time of COVID-19 diagnosis, N (%) | |||||
| Asymptomatic | 5 (12.8) | 3 (9.1) | 14 (13.5) | 22 (12.2) | 0.6 |
| Fever | 26 (66.7) | 19 (54.3) | 46 (43.4) | 91 (50.6) | |
| 45 (60.8) | 46 (43.4) | 0.02** | |||
| Upper respiratory symptoms | 17 (43.6) | 13 (37.1) | 64 (60.4) | 94 (52.2) | |
| 30 (40.5) | 64 (60.4) | 0.02** | |||
| Lower Respiratory symptoms | 15 (38.5) | 13 (37.1) | 23 (21.7) | 51 (28.3) | |
| 28 (37.8) | 23 (21.7) | 0.01** | |||
| Oxygen support, N (%) | 18 (46.2) | 14 (40.0) | 27 (25.5) | 59 (32.8) | |
| 32 (43.2) | 27 (25.5) | 0.01** | |||
| Missing | 0 (0.0) | 3 (8.6) | 3 (2.8) | 6 (3.3) | |
| Invasive mechanical ventilation | 8/18 (44.4) | 7/14 (50.0) | 3/27 (11.1) | 18/59 (30.5) | |
| Hospital admission, N (%) | 32 (82.1) | 23 (65.7) | 46 (43.4) | 101 (56.1) | |
| 55 (74.3) | 46 (43.4) | <0.0001** | |||
| Missing | 0 (0.0) | 2 (5.7) | 0 (0.0) | 2 (1.1) | |
| Median hospital admission duration, days (min-max) | 23.5 (1–93) | 18 (2–82) | 11 (1–280) | 17.5 (1–280) | |
| 21(1–93) | 11 (1–280) | ||||
| ICU admission, N (%) | 15 (38.5) | 10 (28.6) | 6 (5.7) | 31 (17.2) | |
| 25 (33.8) | 6 (5.7) | <0.0001** | |||
| Missing | 1 (2.6) | 1 (2.9) | 0 (0.0) | 2 (1.1) | |
| Median ICU admission duration, days (min-max) | 20.0 (2–68) | 17.5 (7–38) | 7.5 (3–57) | 13.5 (2–68) | |
| 19 (2–68) | 7.5 (3–57) | ||||
B-NHL B-cell Non-Hodgkin Lymphoma.
*Metabolic comorbidities include obesity, hypertension, diabetes, hypercholesterolemia, smoking and cardiovascular disease ** significant. # The P values given in this table are for the comparison of the years 2020 and 2021 combined with the year 2022 ** significant P value.